Clinical Trial Update: A Relative Bioavailability Study Measuring the Extent and Rate of Absorption of Different Tablet Formulations of AZD1656 in Type 2 Diabetes Mellitus (T2DM) Patients [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the relative bioavailability of several AZD1656 tablet formulations in patients with Type 2 Diabetes Mellitus has been completed. The t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperglycemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• AZD1656

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus, High Blood Sugar | Phase 1 | Status: COMPLETED